<DOC>
	<DOCNO>NCT00555061</DOCNO>
	<brief_summary>A study evaluate pharmacokinetics Retapamulin Ointment , 1 % , pediatric subject ( 2-24 month ) secondarily-infected traumatic lesion , secondarily-infected dermatosis , impetigo ( bullous non-bullous ) .</brief_summary>
	<brief_title>Pharmacokinetics Retapamulin Pediatric Subjects With Uncomplicated Skin Infections .</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Inclusion criterion : Subject Age : The subject ≥2 month ≤24 month age study entry Subject Diagnosis : The subject diagnosis secondarilyinfected traumatic lesion ( SITL ) , secondarilyinfected dermatosis ( SID ) , primary impetigo ( bullous nonbullous ) suitable treatment topical antibacterial therapy : The subject small laceration , suture wound abrasion , secondary bacterial infection . The infected portion laceration suture wound exceed 10cm length surround erythema extend 2cm edge wound . Abrasions exceed 2 % total body surface area surround erythema extend 2cm edge abrasion . The subject diagnosis inflammatory skin disease ( i.e. , dermatosis ) , atopic dermatitis contact dermatitis , secondary bacterial infection . The infected portion lesion ( ) exceed 2 % total body surface area . Impetigo : The subject lesion group £10 discrete localize lesion otherwise healthy skin , characterize red spot blister without crust later progress lesion ooze form yellow honeycolored crust surround erythematous margin . Subject SIRS Score : The subject total SIRS score least 8 ( Appendix 1 Skin Infection Rating Scale ) Protocol Compliance : The parent/legal guardian willing comply protocol Informed Consent : The parent/legal guardian give write inform , dated consent subject participate study French Subjects : In France , subject eligible inclusion study either affiliate beneficiary social security category Exclusion criterion : The subject demonstrate previous hypersensitivity reaction pleuromutilin component ointment ( refer Investigator Brochure composition Retapamulin ointment , 1 % ) The subject consider premature birth ( &lt; 37 week gestation ) The subject secondarilyinfected animal/human bite , puncture wind The subject abscess The subject chronic ulcerative lesion unlikely Staphylococcus aureus Streptococcus pyogenes causative agent The subject systemic sign symptom infection ( fever ; define temperature equivalent rectal temperature great 101°F 38.3°C ) The subject bacterial skin infection , due area , depth severity , opinion investigator , appropriately treated topical antibiotic The subject one type infect lesion define protocol The subject require surgical intervention treatment infection prior enrollment study , likely require intervention course study The subject apply topical therapeutic agent ( include glucocorticoid steroid , antibacterial antifungal ) directly infect wound/lesion , within 24 hour prior study entry The subject receive one day treatment systemic antibacterial within 72 hour study entry The subject receive systemic corticosteroid dose &gt; 0.125mg/kg per day prednisone ( equivalent ) The subject know , preexist , serious underlie disease could imminently lifethreatening The subject participate study use investigational drug previous 30 day prior enter study The subject previously enrol study study involve Retapamulin</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>SID</keyword>
	<keyword>impetigo</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Retapamulin ointment , 1 %</keyword>
	<keyword>Skin abnormality</keyword>
	<keyword>Dermatoses</keyword>
	<keyword>pediatric</keyword>
	<keyword>infection</keyword>
	<keyword>SITL</keyword>
</DOC>